A phase 1 study to investigate the effect of single and repeated doses of DSP-2230/placebo on renal function in healthy subjects
Latest Information Update: 05 Nov 2019
At a glance
- Drugs DSP 2230 (Primary)
- Indications Neuropathic pain
- Focus Pharmacodynamics
- Sponsors Sunovion Pharmaceuticals Europe
- 01 Dec 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
- 18 Nov 2013 New trial record